We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Revolutionary Blood Test to Transform Early Diagnosis of Bowel Cancer

By LabMedica International staff writers
Posted on 20 May 2022
Print article
Image: Accurate, non-invasive, inexpensive blood test will help diagnose bowel cancer early (Photo courtesy of Swansea University)
Image: Accurate, non-invasive, inexpensive blood test will help diagnose bowel cancer early (Photo courtesy of Swansea University)

Bowel (colorectal) cancer is the second most common cancer globally. It is the leading cause of cancer-related death in the Western world. Early diagnosis of bowel cancer significantly reduces mortality rate. Current diagnostics tests such as colonoscopy or fecal blood detection kits can be invasive, unpleasant and expensive. Now, an accurate, non-invasive, inexpensive blood test can diagnose bowel cancer early and dramatically cut waiting times for diagnosis while reducing the need for unnecessary invasive procedures such as colonoscopies.

Researchers at Swansea University (Swansea, UK) have devised a simple Raman Spectrometry (RS) blood test which can return test results in under 20 minutes. Using innovations based around laser spectroscopy and artificial intelligence (AI) -based analytics, the test analyses cancer-driven metabolic activity in blood that their AI software is trained to interpret and diagnose. The test aims to break down patient anxiety with a highly accurate test to give rapid reassurance to those who have not got cancer and ensure they do not need an invasive colonoscopy. As a result, this will free up valuable endoscopy and colonoscopy resource and speed up treatment for those who have cancer while resulting in savings from a reduction of needless colonoscopies.

Results from a ground-breaking study involving 27 practices and 595 patients showed 79% of early-stage bowel cancers and 100% of advanced bowel cancers were picked up by the test. Early comparisons with other tests currently available in primary care have shown the RS blood test to have greater sensitivity for the detection of bowel cancer. Currently, a high number of unnecessary colonoscopies are conducted to ensure cases of bowel cancer are detected. Since the start of the pandemic, waiting lists for the procedure have significantly increased. These delays can reduce the chances of patient survival, with many people being diagnosed too late. The blood test hopes to change all that by providing accurate results within 48 hours, preventing unnecessary colonoscopies and relieving pressure on healthcare systems.

Related Links:
Swansea University 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.